Removing dead tissue from deep burns has traditionally required surgical excision, which sacrifices some viable tissue and carries blood loss and grafting consequences. NexoBrid (anacaulase) offered an enzymatic alternative.
Its bromelain-derived proteolytic enzymes selectively dissolve burn eschar while largely sparing the viable tissue underneath, reducing the need for surgical debridement. The topical gel is applied for four hours to remove eschar in adults with deep partial-thickness or full-thickness thermal burns.
NexoBrid has since been approved for pediatric patients, and its development was supported by U.S. biomedical preparedness funding given its relevance to mass-casualty burn events. That government stockpiling interest, alongside routine burn care, shapes its commercial profile.
